# Nurix Therapeutics（NRIX）股價週一飆升，因公司與羅氏（RHHBY）簽訂全球合作及授權協議，共同開發及商業化bexobrutideg。

*biotech · news · 2026-06-08 · Seeking Alpha*

## Key points

- Nurix Therapeutics與羅氏簽訂bexobrutideg全球合作及授權協議。
- 該交易價值高達30億美元，Nurix獲得7億美元前期付款。
- Bexobrutideg是潛在的最佳口服BTK降解劑，用於癌症治療。
- Nurix股價在宣布與羅氏合作交易後飆升43%。

Nurix surges 43% on up to $3B cancer drug deal with Roche Comments Nurix Therapeutics (NRIX) shares surged on Monday after the company entered a global collaboration and licensing agreement with Roche (RHHBY) to develop and commercialize bexobrutideg, a potential best-in-class oral BTK degrader, in a deal worth up to $3B, including a $700M upfront Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities. Subscribe to Newsletters

**Companies:** Roche, Nurix Therapeutics
**Countries:** United States, Switzerland

[Read the full story on Seeking Alpha](https://seekingalpha.com/news/4601297-nurix-surges-43-on-up-to-3b-cancer-drug-deal-with-roche)

---

Canonical: https://newsio.io/zh-TW/n/2a2f06a0-114f-4a6b-a10a-ffe09396e50a/nurix-therapeuticsnrixrhhbybexobrutideg
Summarized by Newsio from Seeking Alpha. https://newsio.io/how-it-works